Immune parameters affecting the efficacy of chemotherapeutic regimens.
about
The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patientsThe promise of immunotherapy in head and neck squamous cell carcinomaEngineered Swine Models of CancerThe Immunogenicity of Colorectal Cancer in Relation to Tumor Development and TreatmentImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsConcepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesCancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateControl of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentImmune Checkpoint Blockade in Cancer TherapyWhat lessons can be learned from γδ T cell-based cancer immunotherapy trials?Immunotherapy advances for glioblastomaTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerUnlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapyTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTrial Watch:: Oncolytic viruses for cancer therapyCancer vaccinesOptimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccinesFasting enhances the response of glioma to chemo- and radiotherapyClinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancerZoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cellsAutophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumorsComplementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancerThe innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress.Immune cells: plastic players along colorectal cancer progressionEffects of acupuncture on leucopenia, neutropenia, NK, and B cells in cancer patients: a randomized pilot study.P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotImmunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Oncolytic immunotherapy: where are we clinically?Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.Combination immunotherapy: a road map.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.Inferring active and prognostic ligand-receptor pairs with interactions in survival regression models.
P2860
Q26738665-8866DD37-71EF-48D3-B076-AC8FD1A228EAQ26744433-5B3DAB22-E59C-49E2-A582-AF0DDFA8B49CQ26744575-14E5271C-5A9E-463A-ACA2-BB1CEE47EB81Q26745580-AFA66972-D7FA-40DC-813F-B46235F2328FQ26765115-179D0A0E-58FD-45F6-AEDA-AB2CF4470485Q26781215-695C5AF2-44A7-4059-ADC0-3729A626AC18Q26782573-DD610E13-5F92-4EB6-BF5A-53B3EA8D8252Q26799117-F9DFAEDE-2986-4A0E-B31C-6DF27F051CA2Q26830509-41F7C491-7245-48CD-B0CE-EE31FA1CAC96Q26849323-EC982C3B-CAC3-403D-99E9-35AA5763DBAAQ26866513-E76B034F-3167-4051-AE9D-32BFCE8F4C37Q26993238-9821A40C-DA69-4E54-ADA1-BA918991378EQ26996829-713B3D13-CD18-4600-AD32-FD123ED8ABC9Q27001216-8FB640B5-1F02-4154-B741-A5EC0A36C703Q27004011-C83AB88A-3B1A-468F-A5EF-B86DE1ACFE4CQ27021951-9E12968D-BBEC-4070-A6B3-152740F9A033Q27024438-6D3A4EA4-A865-4EB9-8996-61464AB80527Q27030560-33520A88-D73A-4462-A224-2E8CB3DE0210Q27320014-66D5122A-F4C7-4B5A-8EDC-2559C375FB33Q28072263-D1ED6145-A94D-4017-928A-319915E7E9B6Q28486174-4D1C5D3B-9D1B-4F22-91FD-3CF6BC9F4E9DQ30402590-EB4FD069-DD06-4741-A21F-005BED5B43F9Q30442426-77E1889E-0B77-4791-9BCB-F12B4724D6E0Q33602876-9FC8EF53-B90E-4479-A3C6-23C89094BF70Q33660069-E0315D98-FEDE-4E33-A8EC-F602136D0CAAQ33724135-E1281601-EF2A-4117-A3DA-B98B1412CF9DQ33776397-5559957E-9A31-4637-8FEF-BDB6509862BDQ33985586-3FC90BE6-DB9D-4A3F-AD8B-65DA01CD9AB1Q34039501-65B1BE88-7B9B-4999-9EF9-D9D643737081Q34152239-0A485A96-DB65-444A-AFD9-BB3395119C9FQ34180369-E559A881-2776-4149-B4CB-D1434E1ADA04Q34312571-06A1C484-F5C2-4678-9DD1-B5F708AB775EQ34361976-728EA6B3-FA3B-4F83-84C4-E537636BF523Q34405325-12CF8ACD-E591-4EDF-8073-3F1E231D803DQ34426949-3ECCF98A-3CF1-4273-8F09-1A69FF5FFF81Q34502899-BA64D12B-AD9B-4A85-8E83-50EDC37BF5C9Q34552128-5CA92843-62B5-4CC7-9ED2-DA8011206A64Q34743969-2B952368-4777-4E77-8487-8721C9739C0FQ35000651-F416C244-5325-4A24-8288-2E599771DBA4Q35026818-5C109AE2-3B78-46DD-BA7F-313B1F0DABC6
P2860
Immune parameters affecting the efficacy of chemotherapeutic regimens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune parameters affecting the efficacy of chemotherapeutic regimens.
@en
Immune parameters affecting the efficacy of chemotherapeutic regimens.
@nl
type
label
Immune parameters affecting the efficacy of chemotherapeutic regimens.
@en
Immune parameters affecting the efficacy of chemotherapeutic regimens.
@nl
prefLabel
Immune parameters affecting the efficacy of chemotherapeutic regimens.
@en
Immune parameters affecting the efficacy of chemotherapeutic regimens.
@nl
P2860
P50
P1476
Immune parameters affecting the efficacy of chemotherapeutic regimens.
@en
P2860
P304
P356
10.1038/NRCLINONC.2010.223
P407
P577
2011-03-01T00:00:00Z